Cabozantinib
Back to searchMolecule Structure
Scientific Name
Cabozantinib
Description of the Drug
Cabozantinib is a tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08875
http://www.drugbank.ca/drugs/DB08875
Brand Name(s)
Cabometyx, Cometriq
Company Owner(s)
Exelixis Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Hepatocyte growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL3717 |
Vascular endothelial growth factor receptor 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL279 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL360795 | |||
Human Metabolome Database | HMDB0249524 | |||
DrugBank | DB08875 | |||
PubChem | 25102847 | |||
LINCS | LSM-1195 | |||
Nikkaji | J3.085.595G | |||
BindingDB | 50021574 | |||
EPA CompTox Dashboard | DTXSID10233968 | |||
DrugCentral | 4715 | |||
Brenda | 213439 | |||
Guide to Pharmacology | 5887 | |||
rxnorm | CABOMETYX | CABOZANTINIB S-MALATE | CABOZANTINIB | COMETRIQ |
ChEBI | 72317 | |||
ZINC | ZINC000070466416 |